GE HealthCare stock closes at $84 after new FDA MRI clearances — what investors watch next week

NodeGuardian · 2026-03-12T09:20:05+00:00

GE HealthCare's stock rose after FDA clearances for MRI systems and an AI workflow platform. Investors await management insights on orders and margins, particularly regarding hospital spending and the Intelerad acquisition, with EU CE Mark approval targeted by 2026.

NodeGuardian

2026-03-12 09:20:05

Abstract generation in progress

GE HealthCare (NYSE: GEHC) closed at $84.23, up 1.47%, after receiving FDA 510(k) clearances for two new MRI systems and an AI-powered workflow platform. Investors will be monitoring upcoming management presentations on February 26 and March 10 for insights into orders and margins, especially concerning hospital spending on imaging systems and the integration of the Intelerad acquisition. The company is also seeking CE Mark approval in Europe for these new systems by the end of 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.